Ensuring appropriate and sustainable use of targeted treatments for analyzing the efficacy, safety, and cost‐effectiveness of PD‐1/PD‐L1 inhibitors on NSCLC is vital.14, 16, 17, 18. This evidence concerns the gene CD274 and non-small cell lung carcinoma.